课题基金 / 基金详情

ACTG395--INDINAVIR IN COMBINATION W/ STAVUDINE & LAMIVUDINE IN HIV INF CHILDREN

ACTG395--INDINAVIR IN COMBINATION W/ STAVUDINE & LAMIVUDINE IN HIV INF CHILDREN
ACTG395--茚地那韦与司他夫定联用
批准号:
6264759
负责人:
RICHARD RUTSTEIN
金额:
$0.06万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

RICHARD RUTSTEIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 395 (and associated protocol Merck 068) evaluates the combination of indinavir (an antiretroviral of the protease inhibitor class) with two nucleoside transcriptase inhibitors (stavudine and lamivudine) in HIV infected children ages 3-18 years. This study closed to accrual of new patients in November, 1998, and we anticipate that treatment and data collection for this study will be extended until at least late 1999 to allow patients to remain on study medications while the FDA reviews the data. No preliminary data are available at this time.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDY OF BMS-232632 IN COMBINATION REGIMENS IN ANTIRETROVIRAL THERAPY
  • 批准号:
    7207692
  • 项目类别:
  • 资助金额:
    $3.56万
  • 财政年份:
    2005
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
PACTG 326: ALVAC HIV VACCINES AND AIDSVAX B/B IN CHILDREN BORN TO HIV MOTHERS
  • 批准号:
    7207785
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2005
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
PACTG 326: ALVAC HIV VACCINES AND AIDSVAX B/B IN CHILDREN BORN TO HIV MOTHERS
  • 批准号:
    7041890
  • 项目类别:
  • 资助金额:
    $2.12万
  • 财政年份:
    2004
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
STUDY OF BMS-232632 IN COMBINATION REGIMENS IN ANTIRETROVIRAL THERAPY
  • 批准号:
    7041819
  • 项目类别:
  • 资助金额:
    $4.2万
  • 财政年份:
    2004
  • 负责人:
    RICHARD RUTSTEIN
  • 依托单位:
海外基金